Knight Cancer Institute

Medicine & Life Sciences

1. Acute Myeloid Leukemia 35%
2. Adenocarcinoma 13%
3. Allogeneic Cells 31%
4. Androgen Receptors 9%
5. Androgens 28%
6. Apoptosis 16%
7. Atlases 9%
8. B-Cell Chronic Lymphocytic Leukemia 23%
9. B-Lymphocytes 11%
10. Biomarkers 14%
11. Biopsy 10%
12. Bone Marrow 30%
13. Bone Marrow Transplantation 9%
14. Breast Neoplasms 28%
15. Calcitriol 14%
16. Calcium-Calmodulin-Dependent Protein Kinase Type 2 15%
17. Carcinoma 12%
18. Castration 42%
19. Cell Line 17%
20. Cell Transplantation 45%
21. Clinical Trials 29%
22. Colorectal Neoplasms 19%
23. Confidence Intervals 18%
24. Cytogenetics 15%
25. Cytokines 9%
26. Dasatinib 15%
27. Docetaxel 30%
28. Drug Therapy 40%
29. Exons 11%
30. Fanconi Anemia 12%
31. Gastrointestinal Stromal Tumors 63%
32. Gene Expression 12%
33. Genes 29%
34. Genome 11%
35. Graft vs Host Disease 20%
36. Granulocyte Colony-Stimulating Factor 9%
37. Growth 16%
38. Hematologic Neoplasms 15%
39. Hematopoietic Stem Cell Transplantation 14%
40. Hematopoietic Stem Cells 18%
41. Hemorrhage 11%
42. Homologous Transplantation 16%
43. Imatinib Mesylate 100%
44. In Vitro Techniques 14%
45. Interferons 9%
46. Leukemia 34%
47. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 61%
48. Leukemia, Myeloid, Chronic Phase 13%
49. Lymphoma 9%
50. Lymphoma, Large B-Cell, Diffuse 12%
51. Mantle-Cell Lymphoma 11%
52. MDV 3100 26%
53. Melanoma 11%
54. Mortality 15%
55. Multiple Myeloma 18%
56. Mutation 59%
57. Myelodysplastic Syndromes 10%
58. Myeloid Cells 13%
59. Neoplasm Metastasis 12%
60. Neoplasms 95%
61. Non-Hodgkin's Lymphoma 14%
62. Pharmaceutical Preparations 19%
63. Philadelphia Chromosome 13%
64. Phosphatidylinositol 3-Kinase 9%
65. Phosphorylation 19%
66. Phosphotransferases 47%
67. Physicians 9%
68. Placebos 18%
69. Population 12%
70. Precursor Cell Lymphoblastic Leukemia-Lymphoma 16%
71. Progression-Free Survival 27%
72. Prostate 12%
73. Prostate-Specific Antigen 21%
74. Prostatic Neoplasms 93%
75. Protein Kinases 9%
76. Protein-Tyrosine Kinases 43%
77. Proteins 24%
78. Radiotherapy 13%
79. Randomized Controlled Trials 12%
80. Receptor Protein-Tyrosine Kinases 9%
81. Recurrence 24%
82. Renal Cell Carcinoma 11%
83. Safety 22%
84. Sarcoma 9%
85. Signal Transduction 9%
86. src Homology Domains 11%
87. Stem Cell Transplantation 17%
88. Stem Cells 21%
89. Sunitinib 11%
90. Survival 54%
91. T-Lymphocytes 17%
92. Therapeutics 62%
93. Thrombosis 10%
94. Tissue Donors 15%
95. Transplantation 17%
96. Transplants 39%
97. Tyrosine 16%
98. Unrelated Donors 16%
99. Young Adult 12%